LivaNova Reenters Medicare Fray Seeking VNS Depression Coverage
Executive Summary
The US Centers for Medicare and Medicaid Services opened a national coverage reconsideration analysis for vagus nerve stimulation for treatment-resistant depression on May 30, 11 years after it declined to cover the treatment for this indication.
You may also be interested in...
LivaNova On The Mend With Stronger, Sharper Focus
LivaNova has had a reboot and its new senior management team, including a new CEO, looks to be steering the $1.2bn cardio-neuro group towards growth. A more stringent focus on the cardiac surgery and neuromodulation businesses – boosted by strategic M&A tuck-ins – are expected to reap short-term wins, while calculated bets on multiple shots on goal will hopefully bring longer-term rewards. As he approaches his one-year anniversary at LivaNova, CEO Damien McDonald chats to Medtech Insight about his journey so far to unlocking the significant potential he believes the company holds.
Cyberonics Refocuses Sales And Marketing Effort On Epilepsy Treatment
Cyberonics will emphasize the epilepsy indication of its VNS vagus nerve stimulation implant in the wake of reimbursement difficulties that have hindered marketing of its depression indication
FDA Eyes Upclassification, Labeling Guidance To Address Stapler Risks
The US agency sent a letter to health-care providers spotlighting its analysis of the increasing numbers of adverse events linked to surgical staplers and implantable staples, and its plans for a draft guidance on labeling and an advisory panel meeting to consider a 510(k) requirement for the products.